EHA Expert Interview with Professor Yang Liang: Immune-Based Insights into Secondary Resistance to Anti-CD38 Therapy in Multiple Myeloma
The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13 to 16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, a study by Professor Yang Liang's team from Sun Yat-sen University Cancer Center on "Bone Marrow Ecosystem Formation and Secondary Resistance to Anti-CD38 Therapy in Multiple Myeloma" was selected for an oral presentation (S198). This study provides significant insights and references for optimizing resistance management in anti-CD38 therapy for multiple myeloma. We invited Professor Yang Liang for an interview to delve into the study's content and its clinical implications, as well as to highlight future research directions in this field.